ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
advertisementadvertisement
Human Immunology
Volume 66, Issue 2, February 2005, Pages 133-139
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (145 K)

 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.humimm.2004.09.018    How to Cite or Link Using DOI (Opens New Window)
Copyright © 2005 American Society for Histocompatibility and Immunogenetics Published by Elsevier Inc.

Impact of TGFβ1 gene polymorphisms on late renal function in pediatric heart transplantation

Sylvie Di Filippoa, Adriana Zeevia, Kevin K. McDadea, Gerard J. Boyleb, Susan A. Millerb, Sanjiv K. Gandhic and Steven A. Webberb, Corresponding Author Contact Information, E-mail The Corresponding Author

aDepartment of Transplant Pathology, University of Pittsburgh School of Medicine, Pittsburgh bDepartment of Pediatric Cardiology, Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvaina, USA cThoracic Surgery, Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvaina, USA

Received 10 September 2004; 
accepted 27 September 2004. 
Available online 18 November 2004.

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Abstract

Late renal dysfunction may affect long-term outcome of nonrenal transplant recipients. We hypothesized that transforming growth factor β1 (TGFβ1) might play a role in the fibrogenic mechanisms leading to renal dysfunction. The aim was to determine whether TGFβ1 gene polymorphisms are associated with renal outcome in pediatric heart recipients. Eighty-eight patients underwent a first heart transplantation at the age of 7.1 ± 6.5 years, received tacrolimus-based immunosuppression, and were followed for ≥1 year (6.7 ± 3.2 years). Creatinine clearance (CrCl; ml/mn/1.73 m2) was calculated (Schwartz) before transplant, then at 1 month, 6 months, and 1 year, and yearly up to 7 years. Impaired function was defined as CrCl <80 ml/mn/1.73 m2. Mean CrCl decreased from 120 ± 53 ml/mn/1.73 m2 before transplant to 98 ± 40, 96 ± 37, 102 ± 30, and 101 ± 38 ml/mn/1.73 m2 at, respectively, 6 months and 1, 5 (n = 58), and 7 years (n = 33). The TGFβ1 high-producer genotype had worse CrCl than intermediate and low producers at every time point, despite similar pretransplant CrCl (pretransplant = 120 ± 53 vs 118 ± 55 ml/mn/1.73 m2 [p = 0.8], 1 year = 92 ± 38 vs 113 ± 30 ml/mn/1.73 m2 [p = 0.03]) and similar tacrolimus levels. The TGFβ1 high-producer genotype was associated with CrCl < 80 ml/mn/1.73 m2. The TGFβ1 high-producer genotype is associated with renal dysfunction in pediatric heart recipients.

Keywords: transforming growth factor beta1; gene polymorphism; renal function; heart transplantation; pediatrics

Abbreviations

CrCl
creatinine clearance
GFR
glomerular filtration rate
TGFβ1
transforming growth factor β1
TGFβ1-H
transforming growth factor β1 high producer genotype
TGFβ1-I/L
transforming growth factor β1 intermediate and low producer genotype

Article Outline

Nomenclature
Introduction
Patients and methods
Results
Population
TGFβ1 distribution
TGFβ1 and renal function
Mean CrCl
Percentage of patients with CrCl <80 ml/mn/1.73m2
CrCl at latest follow-up
Freedom from renal dysfunction: CrCl <80 ml/mn/1.73 m2
Discussion
Acknowledgements
References






Human Immunology
Volume 66, Issue 2, February 2005, Pages 133-139
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.